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Abstract: 
 
Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for 
the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug 
Administration. This unique natural product was discovered from cultures of Chromobacterium 
violaceum, a Gram-negative bacterium isolated from a Japanese soil sample. This bicyclic 
compound acts as a prodrug, its disulfide bridge being reduced by glutathione on uptake into the 
cell, allowing the free thiol groups to interact with Zn ions in the active site of class I and II 
HDAC enzymes. Due to the synthetic complexity of the compound, as well as the low yield from 
the producing organism, analogs are sought to create synthetically accessible alternatives. As a 
T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few 
effective therapies. 
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Article: 
 
Introduction to Histone Deacetylase (HDAC) Inhibitors 
 
Alteration of gene expression because of epigenetic modification of the chromatin structure has 
been implicated as an important factor in tumorigenesis.1,2 In chromatin, DNA is tightly coiled 
around core histone proteins, forming nucleosomes; linker histones bind nucleosomes together as 
chromatin. Methylation, acetylation, phosphorylation, ADP-ribosylation or ubiquitination of the 
histone tail regions affect the binding of the histone proteins to DNA, changing the structure of 
the chromatin and subsequently the accessibility of transcription factors to DNA regions.3 Such 
epigenetic processes alter levels of gene expression without changing the nucleotide sequence.4 
Of these modifications, histone acetylation is the most widely studied, because of its role in the 
development and progression of tumors.2 
 
Histone acetylation is controlled by histone acetyltransferases and histone deacetylases 
(HDACs). Histone acetyltransferases direct the addition of acetyl groups to lysine residues in the 
amino-terminal histone tails, neutralizing that portion of the protein and relaxing the chromatin 
structure, thereby increasing accessibility of transcription complexes as well as recruiting 
transcription cofactors.2, 3, 5, 6 Conversely, HDACs remove acetyl groups from the histone tails, 
resulting in a more compact and inaccessible form of chromatin, consequently silencing 
transcription.2, 3, 5 These effects are highly localized, and only 2–5% of encoding genes are 
transcriptionally regulated by the histone acetylation state.2 Importantly, this selection includes 
genes that control the cell cycle and apoptosis, and HDACs have been associated with several 
well-characterized oncogenes and tumor-suppressor genes.7, 8 Certain tumors have overexpressed 
HDACs and downregulated or mutated histone acetyltransferases.9 It has been suggested that an 
imbalance of HDAC relative to histone acetyltransferase activity can lead to a diminished 
expression of such regulatory genes and ensuing tumorigenesis.9 
 
 
Figure 1. Structures of romidepsin (1) and the reduced counterpart (2). (Note that the structures 
of romidepsin (1) and its reduced counterpart (2) were published incorrectly in the review by 
Grant et al.17) The numbering of 1 is based on Xiao et al.16 
 
HDAC inhibitors have been found to have therapeutic properties in many different human tumor 
cell lines, including those derived from the bladder, breast, prostate, lung, ovary and colon, 
among others,10 indicating that the inhibition of HDAC activity may be a viable strategy for the 
treatment of cancers.11, 12, 13 It is also likely that HDAC inhibitors affect a number of subcellular 
pathways, and time will tell what impact these other mechanisms have on treatment of cancer 
and/or other diseases. HDAC inhibitors can be divided into four classes, namely hydroximates, 
cyclic peptides, aliphatic acids and benzamides.14 A new HDAC inhibitor, romidepsin, which has 
been referred to by several different names in the literature, including FK228, FR 901228, NSC 
630176, depsipeptide and Istodax, is a pentapeptide isolated from cultures of Chromobacterium 
violaceum.15 The bicyclic depsipeptide structure of romidepsin (1, Figure 1) is composed of four 
amino acids (D-valine, D-cysteine, Z-dehydrobutyrine, L-valine) and (3S,4E)-3-hydroxy-7-
mercapto-4-heptenoic acid, and the numbering of 1 is based on Xiao et al.16 (Note that the 
structures of romidepsin (1) and its reduced counterpart (2) were published incorrectly in the 
review by Grant et al.17) Romidepsin was approved by the US Food and Drug Administration 
(FDA) in 2009 for use in patients with cutaneous T-cell lymphoma (CTCL). 
 
Background on CTCL 
 
The incidence of CTCL in the general population is estimated to be 1–4/100 000,18, 19 with 
approximately 1500 new cases and 500 deaths per year in the United States.20 CTCL is twice as 
prevalent in males as in females, and the median age of presentation is 57 years. In the United 
States, the disease is also more common among African Americans than in other race 
categories.19 Approximately, 16 000–20 000 individuals in the United States are affected by 
CTCL.20 One study from 1973 to 1984 found a 3.2-fold increase in the incidence of CTCL over 
that time period;21 a similar study from 1973 to 2002 reported a 3.4-fold increase in incidence 
over the course of the study.22 
 
The most common types of CTCL are mycosis fungoides (MF), so called because early 
physicians believed it to be a fungal infection, although it is not, and Sézary syndrome. The 
latter, the leukemic variant, is characterized by pruritus, generalized exfoliative erythroderma 
and abnormal lymphoid cells in the blood. On the other hand, the blood is usually not affected in 
MF, especially in the early stages. Skin lesions are characterized as patches, plaques or tumors 
that have a ‘bathing trunk’ distribution. The lymphoma may extend to cover a large surface area, 
lymph nodes, and, in later stages, viscera. 
 
MF is the most common type of CTCL, and is characterized by pink or erythematous scaly 
patches and plaques, with varying degrees of scaling and pruritus.23 At the time of diagnosis, the 
majority of patients with MF have limited plaques on ≤10% of their total body surface. However, 
approximately one-third of them have extensive plaques. Relatively small proportions of patients 
present with cutaneous tumors (16%) or generalized erythroderma (12%). Non-skin lesions are 
more likely to be seen in later stage disease, with 8% seen in stage T2, 30% in stage T3 and 42% 
in stage T4. The primary non-skin and non-lymph node sites are lung, gastrointestinal, liver and 
central nervous system. Bone marrow involvement is rare in early stage disease. 
 
CTCL is uniformly fatal. The ultimate cause of death for patients with CTCL is commonly 
infection, particularly sepsis, from Pseudomonas aeruginosa or Staphylococcus aureus, caused 
by chronic skin infection and subsequent systemic infections.24 Prognosis is dependent on age as 
well as disease stage at diagnosis,25 with earlier stage disease associated with higher 5-year 
overall survival and disease-free survival rates than later stage disease. The overall 5-year 
survival rate for patients with MF is 91%, while it is only 40% for those with Sézary 
syndrome.26 Typically, those presenting with early stages of CTCL have a favorable prognosis, 
with around 95% 5-year survival;25, 27, 28 more advanced stages have lower survival rates ranging 
from 30 to 84%,25, 27, 28 again depending on form and stage of the cancer. According to one 
study, the 10-year survival rate drops from around 100% for those with stage T1 CTCL to 67% 
for T2; by stage T3, this number drops to 40%.29 Although most patients present with the early-
stage disease, approximately 10–20% of these will progress to a later and often fatal 
disease.25, 27, 30 Patients that undergo transformation to large-cell lymphoma have a mean survival 
ranging from 2 to 19 months.30 
 
Discovery and development of romidepsin 
 
Romidepsin was discovered in the early 1990s through a program that was evaluating 
fermentation products for antimicrobial and antitumor activities. The producing organism, C. 
violaceum, is a Gram-negative, rod-shaped bacterium with a single polar flagellum. The strain 
was isolated from a soil sample collected in the Yamagata-prefecture, Japan.15 Presently, the 
commercial supply of romidepsin is generated via fermentation, although the yield and exact 
conditions are proprietary. 
 
C. violaceum was cultured in nutrient broth with additional glucose and incubated at 30 °C 
aerobically with agitation. The organism reached stationary phase after 72 h, providing a 
maximal yield of romidepsin at this time of 19 μg ml–1, which was present in the aqueous part of 
the culture. The fermentation was filtered, and the filtrate extracted twice with EtOAc. The 
extract was evaporated in vacuo to give an oily residue, which was then purified via normal 
phase chromatography to yield a yellow powder. 
 
This powder was dissolved in CH2Cl2:CH3OH:CH3CN (10:1:20), and romidepsin crystallized as 
colorless prisms. It displayed weak antifungal but no antibacterial activity, but it showed potent 
cytotoxicity against several human lung carcinoma cell lines, as well as human stomach, breast 
and colon adenocarcinoma cell lines.15 The structure of romidepsin (1), which is a cage-shaped 
bicyclic depsipeptide, was determined using a combination of spectroscopic techniques, 
primarily NMR and X-ray crystallography.31 
 
Romidepsin demonstrated the ability to reverse the effects of the rasoncogene in vitro, which has 
been shown to have a role in tumor development; expression of the Ha-ras oncogene appears to 
be directly correlated with tumorigenic potential.32 As a result of romidepsin's ability to reverse 
the ras-transformed phenotype to normal, as well as its cytotoxic effects, it was developed 
initially by the US National Cancer Institute (NCI) as an anti-ras compound,33, 34 but recently it 
has been shown to be an HDAC inhibitor.35, 36 A program screening a number of known 
microbial metabolites for transcriptional activation of the SV40 promoter identified romidepsin 
as an antitumor compound.35 Comparison of its activity to that of trichostatin A (a known HDAC 
inhibitor) revealed that romidepsin was a new HDAC inhibitor.35 
 
Defining a clear path for the development of romidepsin was complicated somewhat because of 
the many different parties involved. Fujisawa Corporation (now Astellas) discovered the 
compound in the early 1990s via a search for molecules that would revert the ras-driven 
oncogenic phenotype, and then, under a Cooperative Research and Development Agreement, 
further oncology investigations were initiated by the US NCI in 1998. When the NCI confirmed 
that romidepsin was a powerful anticancer agent, Fujisawa Corporation initiated their own, 
separate clinical trials program in 2002. Romidepsin was licensed to Gloucester Pharmaceuticals 
in 2004; the company was later acquired by Celgene Corporation (Summit, NJ, USA) in 2010. 
Gloucester approached the US FDA (beginning in 2004), obtained both Orphan Drug Status and 
Fast Track Status, and were able to come to an agreement, through the FDA Special Protocol 
Assessment process, on a path to approval, which was a pivotal single arm (phase II) design, 
although data from the NCI's ongoing study was also to be part of the new drug application 
filing. Essentially, the activity of romidepsin, coupled with the unmet medical need in CTCL, 
were persuasive enough arguments to move the drug forward. 
 
Mechanisms of action 
 
Romidepsin is converted in cells to its active form by the reduction of the disulfide bond by 
glutathione, resulting in a monocyclic dithiol (2, Figure 1),16, 37 and thus romidepsin serves as a 
prodrug that is activated only after uptake into cells. This reduced form of romidepsin (2) is 
inactivated rapidly in serum, perhaps due to sequestration by serum proteins.37 A cysteine in the 
active site pocket (Cys-151 in HDAC1) was thought to covalently bind with the reduced sulfur 
atom at position 13, but a mutant HDAC1 in which Cys-151 was replaced by a serine was still 
sensitive to romidepsin, though a higher concentration (∼eightfold) of the drug was necessary for 
inhibition.37 This fact, combined with the reversibility of the inhibition, suggests that while the 
cysteine may have a role in the affinity of the drug, it most likely does not bind covalently to the 
sulfur atom.37 Crystallographic and computer modeling studies using a HDAC-trichostatin A 
complex suggested that one of the thiol groups of the reduced depsipeptide interacts with zinc 
ions in the active site pocket of certain enzymes, preventing access of the substrate.38 A 
computer modeling study by Furumai et al.37 concluded that when interacting with HDAC1 the 
sulfur atom of the reduced romidepsin was located at a position that allowed interaction with the 
zinc ion via a water molecule. They also suggested that, based on a similar mechanism in 
protease inhibitors, the sulfur may tetrahedrally coordinate with the zinc, displacing the water 
molecule.37 The interaction between the thiol group and the active site of the enzyme prevents 
other substrates from binding. 
 
The reduced form more strongly inhibits HDAC1 and HDAC2 enzymes (class I) than HDAC4 
and HDAC6 enzymes (class II).37 By inhibiting class I HDAC, romidepsin inhibits the removal 
of acetyl groups from the lysine residues of N-terminal histone tails, maintaining a more open 
and transcriptionally active chromatin state.5 In addition, romidepsin also results in altered 
acetylation of other nuclear and cytoplasmic proteins, although the precise pathways by which it 
affects the cell cycle, apoptosis and angiogenesis have not been defined completely.39 
 
Cell cycle arrest 
 
The induction of growth arrest and/or apoptosis by romidepsin depends on the cell line tested 
and the concentration of drug applied.39 Growth arrest, as opposed to apoptosis, is the 
predominant response in cell lines in which the application of romidepsin induces the expression 
of the p21 tumor-suppressor gene.40 Cell lines with reduced p21 expression preferentially 
undergo apoptosis.41 Tumor cells are more susceptible to romidepsin than normal cells,15 a fact 
that leads to a viable therapeutic index in the clinic. 
 
Direct acetylation of non-histone proteins may also trigger growth arrest or apoptosis, and 
several pathways have been studied, although the complete role of HDAC inhibitors is not fully 
understood. Exposure of whole cells to romidepsin results in a decrease in cyclin D1 and c-Myc, 
accompanied by an increase in p53-independent p21 WAF1/Cip 1 induction. The p21 induction 
leads to inhibition of cyclin-dependent kinase and dephosphorylation of the retinoblastoma 
protein, which results in early G1 phase cell cycle arrest.42, 43 A different mechanism involves 
altered expression of cyclin A and D, and p27/Kip1, again resulting in reduced cyclin-dependent 
kinase activity and cell cycle arrest.43 
 
Apoptosis 
 
There are two mechanisms leading to apoptosis: the death receptor pathway and the intrinsic 
pathway.44 Although exposure to romidepsin and other HDAC inhibitors can lead to hyper-
acetylation of death receptor promoters, including tumor-necrosis factor-related apoptosis-
inducing ligand, death receptor 5, Fas ligand and Fas,45 the significance of this mechanism does 
not seem to be universally acknowledged. Some leukemia cells do not show induction of the 
tumor-necrosis factor-related apoptosis-inducing ligand or Fas pathways, or undergo apoptosis 
after exposure to HDAC inhibitors.46 The intrinsic pathway involves the perturbation of 
mictochondrial membranes resulting in the generation of reactive oxygen species. In normal cells 
exposed to HDAC inhibitors, reactive oxygen species do not accumulate because of breakdown 
by thioredoxin; some tumor cells that do not express the thioredoxin gene accumulate reactive 
oxygen species and undergo apoptosis.44 
 
Romidepsin has also been shown to increase acetylation of the HSP 90 chaperone protein, 
causing proteasomal degradation and inducing apoptosis.47 The proteasome inhibitor bortezomib 
appears to work synergistically with HDAC inhibitors,48 but it is interesting that the HSP 90 
inhibitor, geldanamycin, antagonizes HDAC inhibitor activity.49 
 
Angiogenesis inhibition 
 
Romidepsin inhibits hypoxia-induced angiogenesis of endothelieal cells in vitro, but does not 
cause cytotoxicity. It decreased angiogenesis in a chick embryo model, with no signs of 
thrombosis or hemorrhage, and inhibited angiogenesis strongly in mouse model 
tumors.50 Romidepsin appears to reduce angiogenic-stimulating factors such as vascular 
endothelial growth factors, vascular endothelial growth factor receptor, FLT1 and FLK1, and 
increases induction of angiogenic inhibitory factors VHL and neurofibromin 2;50 however, the 
correlation between anti-vascular endothelial growth factor activity and in vivo efficacy has not 
been established. 
 
Pharmacology 
 
Pharmacokinetics 
 
A two-compartment model with linear kinetics can be used in the pharmacokinetic analysis of 
romidepsin.51, 52 Two dosing schedules were studied in separate phase I trials. One schedule 
involved a 4-h infusion on days 1 and 5 of a 21-day cycle, where the maximum tolerated dose 
(MTD) was determined as 17.8 mg m–2,52 while the second involved a 4-h infusion on days 1, 8 
and 15 of a 28-day cycle, where the MTD was determined as 13.3 mg m–2.53 With both 
schedules, romidepsin exhibited linear pharmacokinetics up to the MTD.52, 53 Total clearance 
volumes in adults have been reported as 4.8 l h–1 m–2 at a 13 mg m–2 dose,54 and 10.5 l h–1 m–2 at a 
17.8 mg m–2 dose.52 A phase I study in pediatric patients (2–21 years, median age 13) with 
refractory solid tumors who received romidepsin in 4-h infusions of 17 mg m–2 reported a 
clearance volume of 6.8 l h–1 m–2.55 The elimination half-life has been reported as 3.5 h51 and 
3.67 h54 at 13 mg m–2, and 8.1 h52 at 17.8 mg m–2. 
 
Pharmacodynamics 
 
A typical assay for pharmacodynamic studies is to monitor histone acetylation of peripheral 
blood mononuclear cells (PBMCs).52, 55, 56 Increased acetylation is observed in PBMCs of 
patients after treatment with romidepsin, with maximal accumulation of acetyl H3 histones in 
PBMCs occurring at 4 h after the end of an infusion.55 A study in patients with acute 
myelogenous leukemia and chronic lymphocytic leukemia using a 4 h 13 mg m–2 infusion on 
days 1, 8 and 15 of a 28-day cycle reported 100% histone acetylation of H3 and H4 histones for 
all chronic lymphocytic leukemia patients after 4 h, and for six out of seven chronic lymphocytic 
leukemia patients after 24 h.54 This study also reported an increase in p21 protein expression 
concurrent with H4 acetylation of the p21 promoter gene.54 
 
A phase II study of T-cell lymphoma patients monitored several biomarkers: PBMCs histone 
acetylation, ABCB1 gene expression in PBMCs, ABCB1 gene expression in biopsy samples and 
blood fetal hemoglobin (HbF) levels.57 A global increase in PBMCs histone acetylation was 
reported in 73% of patients within 4 h of treatment, and in 40% of patients after 24 to 48 h.57 The 
number of patients having a twofold or higher than baseline ABCB1 expression in PBMCs was 
56% at 4 h, and 30% at 48 h.57 A fourfold or greater increase in circulating HbF was reported in 
60% of the patients. The histone H3 acetylation in PBMCs at the 24-h time point appeared to 
correlate with response; there was no correlation between the levels of ABCB1 induction and 
pharmacokinetic parameters, or between ABCB1 induction in biopsy samples and clinical disease 
response.57 These data suggested that peak drug concentration (Cmax) and overall exposure were 
important in determining response.17, 57 
 
T-cell lymphoma clinical trials 
 
In preclinical studies, greater antitumor activity was observed with intermittent administration 
than with daily administration.52 Short infusions (>30 s to 4 min) and prolonged infusions (>24 h) 
caused greater toxicity than infusions of 1–4 h.52 Therefore, in phase I trials, romidepsin was 
tested using a 4-h i.v. infusion. Patients who consent to be treated in phase I trials have cancers 
for which no known standard therapy exists, or such therapy has already failed, so that patients 
are not denied any curative or definitely life-extending options. One phase I study52 administered 
a 4-h infusion on days 1 and 5 of a 21-day cycle; the MTD was defined at 17.8 mg m–2 with 
dose-limiting toxicity manifest as grade-3 fatigue, grade-3 nausea and vomiting, grade-4 
thrombocytopenia (low platelet levels) and grade-4 cardiac arrhythmia. Another phase I 
study53 administered romidepsin in a 4-h infusion on days 1, 8 and 15 of a 28-day cycle; the 
MTD in this trial was defined at 13.3 mg m–2 with dose-limiting toxicity manifesting as grade 3 
thrombocytopenia and fatigue. A partial response was seen in a patient with renal cell 
carcinoma.52 Several patients with T-cell lymphoma (cutaneous or peripheral) exhibited 
significant reductions in skin lesions and tumor size after treatment with romidepsin.53, 58 
 
Owing to the dramatic responses seen in phase I trials, a phase II trial to define the response rate 
and toxicity profile in patients with T-cell lymphoma was initiated.40 Romidepsin was 
administered via a 4-h infusion on days 1, 8 and 15 of a 28-day cycle. Complete responses were 
observed in 4 patients (6%), and partial responses were observed in 20 patients (28%).59 The 
toxicities observed were consistent with those reported previously, including extreme fatigue, 
nausea and vomiting.52 Granulocytopenia (failure of bone marrow to make white blood cells) and 
thrombocytopenia (low platelet counts) were observed as well, with values returning to baseline 
by the next cycle of treatment.59 
 
Table 1. Clinical trials of romidepsin 
Phase Target disease Number of 
patients 
Dose and 
schedule 
Outcome References 
I Advanced or refractory neoplasms 37 
17.8 mg m2 
Day 1 and 5 of a 
21-day cycle 
Dramatic response in two patients with 
T-cell lymphoma 52, 58 
II 
Cutaneous and 
peripheral T-cell 
lymphoma 
98 
14 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
34% response rate, complete response in 
four patients. Cardiac pharmacokinetic, 
and pharmacodynamic data acquired 
51, 57, 59, 60 
II Refractory cutaneous T-cell lymphoma 96 
14 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
34% response rate, six patients with 
complete response 61 
I Advanced cancers 33 
13.3 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
No demonstrated activity 53 
I 
Chronic lymphocytic 
leukemia and acute 
myeloid leukemia 
10 (CLL), 
10 (AML) 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
Some clinical activity; more evident anti-
leukemic activity in CLL patients 54 
I 
Children with 
refractory or recurrent 
neoplasms 
18 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
No objective responses 55 
I-II 
Acute myelogenous 
leukemia and advanced 
myelodysplastic 
syndromes 
9 (AML), 
3 (MDS) 
18 mg m2 
Day 1 and 5 of a 
21-day cycle 
Limited clinical activity, although results 
indicated genetics may play a role in 
patient response to the drug 
56 
II Acute myeloid leukemia 20 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
Limited antileukemic activity, possibility 
for combination therapy 62 
II Colorectal cancer 25 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
No objective responses 63 
II Lung cancer 19 
17.8 mg m2 
Day 1 and 7 of a 
21-day cycle 
Limited clinical activity, possibility for 
combination therapy 64 
II Refractory metastatic renal cell cancer 26 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
Limited clinical activity 65 
II 
Metastatic castration-
resistant prostate 
cancer 
35 
13 mg m2 
Day 1, 8 and 15 
of a 28-day cycle 
Limited antitumor activity, possibility 
for combination therapy 66 
Abbreviations: AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; 
MDS, myelodysplastic syndrome. 
 
 
Clinical trials of romidepsin 
 
Table 1 highlights the published clinical trial data on romidepsin; all of the phase I trials were on 
patients who had non-responsive cancers. The favorable results of the NCI-sponsored multi-
institutional phase II trial,51, 57, 59, 60 followed by consistent results by the pivotal phase II trial 
conducted by Gloucester Pharmaceuticals61 led to the approval by the US FDA in November of 
2009. 
 
Toxicity and side effects 
 
Cardiac toxicities were a primary concern in the early clinical trials because of preclinical 
results, leading to electrocardiograms (ECGs) and other measures related to cardiac function 
being taken before and after every treatment.52 Many of the early toxicities were abnormalities of 
the ECG waveform, which represent repolarization abnormalities in the electric functioning of 
the heart; grade 1 T-wave flattening or grade 2 ST segment depression was observed in more 
than half of the ECGs, but although these abnormalities can also be indicative of cardiac 
ischemia, in the case of romidepsin this was not so, because they were not associated with 
elevation of cardiac troponin or with altered left ventricular function.60 Further follow-up over 3 
years with a larger body of clinical data confirms that the ECG abnormalities are not clinically 
significant nor indicative of any real cardiac toxicity.39 Therefore, this observation is no longer a 
clinical concern, except that patients are screened with an ECG to check for pre-existing cardiac 
rhythm abnormalities, including the very rare congenital long QT syndrome, which is a condition 
where the interval between the Q-wave and the T-wave on the ECG is prolonged, and this can 
lead to further, even fatal, problems if the electrical circuitry of the heart is further affected in 
these patients. 
 
The majority of patients receiving romidepsin experience nausea, vomiting and 
anorexia,17, 52, 54, 59, 65 and Grant et al.17 note that the antiemetic routine followed at the NCI was 
to administer 1 mg granisetron i.v. before romidepsin, followed by 1 mg orally every 12 h for 3 
days.17 Progressive fatigue and occasional fever were also noted with 
romidepsin.52, 53, 54, 59, 65 Also of concern are the hematological side effects; regular blood tests 
are administered to patients on romidepsin to monitor these symptoms. (This information comes 
from the package insert.) Leukopenia, granulocytopenia and thrombocytopenia were all 
observed; in each case the effect is quickly reversed after cessation of the treatment.17, 59 
 
Synthetic studies 
 
The main challenges in romidepsin synthesis include the asymmetric construction of the hydroxy 
mercapto heptenoic acid unit, the 16-membered cyclic depsipeptide ring itself (that is, four 
amino acids and hydroxy mercapto heptenoic acid), and the intramolecular oxidative coupling of 
the thiol moieties to produce the stable prodrug form of the molecule. The total synthesis was 
first completed in 1996 in 14 steps with an 18% overall yield.67 An improved synthesis utilizing 
nine steps with a 13% overall yield was published in 2007,68 using, as in the first scheme, an 
asymmetric acetate aldol reaction and a lactonization step for macrolization. In 2008, Wen et 
al.69 utilized a lactamization as an alternative route to cyclization, reporting increased cyclization 
efficiency. However, due both to the chemical complexity of synthesis and the low yield of the 
producing organism, development was hindered mainly by shortages of the product.70 Therefore, 
attempts have been made to develop active analogs. 
 
Using a series of synthetic analogs, Yurek-George et al.71 were able to examine the importance 
of several features of the romidepsin structure. They concluded that while the thiol group at 
position 13 does indeed function as a Zn-binding group within the HDAC active site, the 
cysteine residue is non-essential, provided that the Zn-binding thiol remains protected as in the 
oxidized pro-drug form.71 This assertion is supported by work done with linear compounds in 
which the thiol was masked as a thioester, undergoing enzymatic hydrolysis in the cell to 
produce the free thiol.72, 73 Yurek-George et al. also found that the unsaturated Z-
dehydrobutyrine residue, which could be susceptible to a Michael addition, could be replaced by 
less reactive side chains (for example, 3 and 4, Figure 2) with no loss in in vitro potency, but that 
the macrocyclic scaffold itself was an essential component of HDAC inhibition.71 However, 
several small methyl ester structures without the macrocyclic backbone have proved to induce 
hyperacetylation in Drosophila S2 cells.74 These structures retain the disulfide link of 
romidepsin, thus preserving its prodrug quality. The analogs studied consisted of several small 
cyclic disulfides; the number of methylene units in the ring was varied to provide a range of 
lengths for the linker from the ester to the reduced thiol group.74 Studies with HDAC inhibitors 
trichostatin A and suberoylanilide hydroxamic acid (SAHA) showed important interactions 
between the drugs and several phenylalanine residues surrounding the enzyme active site 
pocket,38 so the methyl ester was used to attach various lipophilic caps, in an effort to improve 
enzyme interaction.74 
 
 
Figure 2. Structures of two romidepsin analogs (compounds 3 and 4), where the Z-
dehydrobutyrine (Z-Dhb) residue, which may be susceptible to a Michael addition, has been 
replaced with a valine moiety.71 
 
Despite these interesting medicinal chemistry studies, to the best of our knowledge, no analogs 
of romidepsin are in advanced stages of development. 
 
 
Conclusions 
 
Romidepsin, a potent HDAC inhibitor, offers a promising new treatment for a disease with few 
existing therapies. This natural product was approved by the US FDA in November of 2009 for 
use in patients with CTLC under the trade name Istodax marketed by Celgene Corporation. The 
dosing schedule was approved as 14 mg m–2 on days 1, 8 and 15 of a 28-day cycle.(This 
information comes from the package insert.) After a year of approval as an antineoplastic agent, 
preliminary information suggests that romidepsin is finding a real place in the treatment of 
CTCL, and the activity and manageable toxicity are helpful for both patients receiving treatment 
and doctors prescribing it (personal communication by several medical doctors to WM). At the 
time of preparation of this review, a supplemental new drug application was being prepared for 
peripheral T-cell lymphoma,75 and only time will tell if romidepsin's use expands to the 
treatment of other cancers. 
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